Authorized or Off-Label Use? A Structured Analysis of Summaries of Product Characteristics with Regard to Authorization in Pediatrics.
Markus HerzigSimone EisenhoferMeike RuschkowskiAntje NeubertAstrid BertscheThilo BertscheMartina Patrizia NeiningerPublished in: Pharmaceutical medicine (2024)
For about a quarter of all indications, no or only ambiguous information was available for pediatric patients. The measures initiated in recent years to increase pediatric-specific information in SmPCs should be intensified in order to improve drug safety in children and adolescents.